We thank CAPES-Brazil, CNPq-Brazil, FAP/DF for financial support. We are grateful to Dr. Hugo Costa Paes for revising the manuscript.

1. Solutions and Media
<ol>
	<li>Prepare 2X Roswell Park Memorial Institute (RPMI) 1640 medium, phosphate buffered saline (PBS), Sabouraud dextrose broth, and Sabouraud dextrose agar as per Table 1.</li>
</ol>
2. Fungal Inoculum Growth Conditions
<ol>
	<li>Store all fungal strains as frozen stocks in 35% glycerol at -80 &#176;C, until needed.</li>
	<li>Perform the following steps before each experiment.
	<ol>
		<li>For Candida albicans strains:
		<ol>
			<li>Thaw a stock vial and transfer 200 &#181;L to 10 mL of Sabouraud dextrose broth in a sterile 50 mL polypropylene tube with a cap and culture overnight at 30 &#176;C with agitation (200 rpm). Remember to incline the tube and leave the cap slightly open for better aeration of the culture.</li>
		</ol>
		</li>
		<li>For Cryptococcus neoformans strains:
		<ol>
			<li>Scrape the frozen surface of a stock vial. Plate the cells onto Sabouraud dextrose agar plates and incubate for 48 h at 30 &#176;C. After visible growth of isolated colonies, keep the plates in the refrigerator (4 &#176;C) sealed with paraffin film for up to 15 days.</li>
			<li>Collect a medium-sized isolated colony from the plate using a sterile toothpick or sterile inoculating loop and inoculate 10 mL of Sabouraud dextrose broth in a sterile 50 mL conical tube. Incubate for approximately 24 h at 30 &#176;C under agitation (200 rpm).</li>
			<li>Do not exceed the 24 h incubation. Remember to incline the tube and leave the cap slightly open for better aeration. It is always good to standardize the growth stage of the cells before each test, since this is an important factor affecting antimicrobial resistance. 
			NOTE: Both fungi were grown at 30 &#176;C for rapid propagation in our experiments, but the temperature can be changed to reflect the aims of the study, for example clinical treatment (37 &#176;C). Most importantly, this initial incubation time should be established beforehand for each fungal isolate and maintained throughout all the tests to ensure reproducibility.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>After fungal growth, collect the cells by centrifuging the conical tubes at 1,200 x g for 5 min at room temperature. Discard the supernatant and add 10 mL of PBS.</li>
	<li>Resuspend the cells and centrifuge again at 1,200 x g for 5 min at room temperature.</li>
	<li>Repeat the PBS wash and centrifugation twice more. After the third wash, resuspend the cells in 5 mL (according to the pellet size) of 2X RPMI-1640 medium.</li>
	<li>Prepare 1 mL of a 1:100 or 1:1,000 dilution in a microcentrifuge tube (depending on the turbidity of the cell suspension).</li>
	<li>Aliquot 10 &#181;L of this dilution, place it in a hemocytometer chamber and count the total number of cells in the four corner quadrants under the microscope. Calculate the concentration by the formula: (total cell number/4) x dilution factor x 104 (chamber dilution constant).
	<ol>
		<li>Consider a 100% viability if viability counts and growth conditions have been systematically correlated for the isolate being studied. 
		NOTE: The standardization and quality control of viability counts can be done by back-plating in accordance to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) antifungal Minimum Inhibitory Concentration (MIC) method for yeasts10.</li>
		<li>If the growth/viability correlation has not been established for the isolate under study, measure the fungal viability by counting live cells in a hemocytometer with the aid of dyes that selectively color dead cells, such as phloxine B11, trypan blue12, or Janus Green13. Use the fungal cells for this protocol only if the viability of the population at this point is 90% or above. 
		NOTE: Dead/alive dyes may not work well with the fungus of choice. Please test them before use. For example, the trypan blue dye does not work well with C. neoformans.</li>
	</ol>
	</li>
	<li>After that, prepare the cell suspensions in 2X RPMI-1640 medium (2X adjusted inoculum in RPMI-1640 medium). For 96-well plates consider a volume of 5 mL for each plate.
	<ol>
		<li>For all C. albicans strains, prepare a stock cell suspension of 4 x 103 cells/mL. This concentration is 2X of the final cell concentration in each well (2 x 103 cells/mL).</li>
		<li>For C. neoformans strains, prepare a stock culture of cells 2 x 104 cells/mL. This concentration is twice the final cell concentration in each well (1 x 104 cells/mL).</li>
		<li>For other fungi, test with a known antifungal which concentration will be ideal for the particular study in relation to the incubation time. Take metabolism and duplication time of the fungus into consideration.</li>
	</ol>
	</li>
</ol>
3. Peptides (Unknown Agent)
<ol>
	<li>Store the lyophilized peptides at -20 &#176;C, and dissolve them in deionized water before each experiment. The maximum storage time once dissolved in water will depend on the nature of each peptide.</li>
	<li>Prepare aliquots of twice the highest final concentration tested in the assay (2X). Ideally, prepare a small number of aliquots with enough peptide for one time use to avoid freeze-thaw cycles. 
	NOTE: The choice of concentration should be based on literature and the properties of the peptide. It is recommended to start the serial dilutions with approximately 100 &#181;M of the peptide, and then decrease or increase this concentration range depending on the obtained results.</li>
</ol>
4. Reference Antifungals (Positive Controls)
<ol>
	<li>For those diluted in water: prepare a 2X solution of the highest concentration of the analysis (see Section 5: Antifungal Assay for the dilution steps).
	<ol>
		<li>For C. albicans strains, prepare a solution of 128 &#181;g/mL of fluconazole or 128 &#181;g/mL of caspofungin. The plate concentration for both will be 64 &#181;g/mL.</li>
		<li>For C. neoformans strains, prepare a solution of 32 &#181;g/mL of amphotericin B (water-soluble solution). The plate concentration will be 16 &#181;g/mL. 
		NOTE: Normally amphotericin B is diluted in dimethyl sulfoxide (DMSO), since this anti-fungal is poorly soluble in water. However, there are water-soluble amphotericin B preparations commercially available.</li>
	</ol>
	</li>
	<li>For antifungals diluted in an organic solvent: prepare a 100X stock solution in DMSO, then dilute it to 10X in water for use. 
	NOTE: Thus, in the well, the final concentration of DMSO will not exceed 1%. A well where the fungus will grow in media containing 1% DMSO as control is required given that some fungi do not tolerate well this concentration of the solvent. Remember that DMSO is photosensitive, so cover the plate with foil or place it in a dark chamber for the duration of the incubation period.</li>
</ol>
5. Antifungal Assay
NOTE: In vitro antifungal assays are performed based on the broth microdilution susceptibility test from Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines with some modifications.
<ol>
	<li>Prepare a two-fold serial dilution of each peptide and control antifungal in 96-well polystyrene microplates to a final volume of 50 &#181;L.
	<ol>
		<li>Using a pipette add 100 &#181;L of the antifungal/peptide in the 2X concentration of the highest desired final concentration in columns 1-3, in row A.</li>
		<li>Using a multichannel pipette, add 50 &#181;L of sterile water into the other wells, in rows B to H.</li>
		<li>Remove 50 &#181;L of the wells with the highest concentration (row A), transfer to the next well of the next concentration (row B) and homogenize.</li>
		<li>Repeat the above steps until the well with the lowest concentration and discard 50 &#181;L of this well (row H). Leave Columns 11 and 12 (rows A, B, C) with only water for either blank control or negative/growth control.</li>
		<li>Add 50 &#181;L of the 2X adjusted inoculum in RPMI-1640 medium to each well (columns 1-3 plus column 11 (negative/growth control)); the final concentration for C. albicans will be 2 x 103 cells/mL, and the final concentration for C. neoformans strains will be 104 cells/mL.</li>
		<li>Prepare blank controls (50 &#181;L water + 50 &#181;L 2X RPMI-1640 medium without cells) and negative/growth control (50 &#181;L water + 50 &#181;L adjusted inoculum 2X RPMI-1640 medium without antifungal), and load into the well plate as described above.</li>
	</ol>
	</li>
	<li>Repeat the procedure for each compound to be tested and the chosen antifungal control (columns 4-10). 
	NOTE: The serial dilutions can be done vertically as the experiment below, or horizontally in the plate (i.e., if the number of dilutions of the given compound/extract that needs to be tested is eight or more).
	<ol>
		<li>If the compounds, reference drugs, or any of its components are photosensitive, perform the assay in reduced light, cover the plates with foil, or place in a dark chamber during incubations.</li>
	</ol>
	</li>
	<li>Consider the following optional recommendations.
	<ol>
		<li>Seal the plate with a clear cover plate that permits gas exchange, as this helps reduce evaporation.</li>
		<li>Place the plate in a humid chamber; it will also help reduce evaporation.</li>
	</ol>
	</li>
	<li>Incubate the plates at 37 &#176;C for 24 h or 48 h for all C. albicans strains, and for 48 h with 200 rpm shaking for C. neoformans. The lower final volume (100 &#181;L) ensures that no spillover occurs. 
	NOTE: No significant difference was observed between MIC readings at 24 h and 48 h for C. albicans strains. Nonetheless, readings at 48 h are easier to visualize.</li>
	<li>Observe all wells, with the assistance of an inverted optical microscope, before the incubation period and after to verify changes in morphology as well as to check for signs of contamination. 
	NOTE: Readings can be done visually and photographed at the end of the experiment. Before each reading, homogenize slightly the plate. The reads can also be performed by measuring its OD at 600 nm, if cell clumps or filamentation are not observed.</li>
	<li>Perform the experiments at least three times on separate dates.</li>
</ol>

<ol><li>Armstrong-James, D., Meintjes, G., Brown, G. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+neglected+epidemic%3A+fungal+infections+in+HIV%2FAIDS%5BTitle%5D)+AND+%22Trends+Microbiol%22%5BJournal%5D)">A neglected epidemic: fungal infections in HIV/AIDS.</a> Trends Microbiol. 22 (3), 120-127 (2014).</li>
<li>Romani, L. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/21394104">Immunity to fungal infections.</a> Nat Rev Immunol. 11 (4), 275-288 (2011).</li>
<li>Pfaller, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antifungal+drug+resistance%3A+mechanisms%2C+epidemiology%2C+and+consequences+for+treatment%5BTitle%5D)+AND+%22Am+J+Med%22%5BJournal%5D)">Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.</a> Am J Med. 125 (1 Suppl), S3-S13 (2012).</li>
<li>Hancock, R. E., Diamond, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+cationic+antimicrobial+peptides+in+innate+host+defences%5BTitle%5D)+AND+%22Trends+Microbiol%22%5BJournal%5D)">The role of cationic antimicrobial peptides in innate host defences.</a> Trends Microbiol. 8 (9), 402-410 (2000).</li>
<li>Wang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Snake+cathelicidin+from+Bungarus+fasciatus+is+a+potent+peptide+antibiotics%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics.</a> PLoS One. 3 (9), e3217(2008).</li>
<li>Du, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((AaeAP1+and+AaeAP2%3A+novel+antimicrobial+peptides+from+the+venom+of+the+scorpion%2C+Androctonus+aeneas%3A+structural+characterisation%2C+molecular+cloning+of+biosynthetic+precursor-encoding+cDNAs+and+engineering+of+analogues+with+enhanced+antimicrobial+and+anticancer+activities%5BTitle%5D)+AND+%22Toxins+%28Basel%29%22%5BJournal%5D)">AaeAP1 and AaeAP2: novel antimicrobial peptides from the venom of the scorpion, Androctonus aeneas: structural characterisation, molecular cloning of biosynthetic precursor-encoding cDNAs and engineering of analogues with enhanced antimicrobial and anticancer activities.</a> Toxins (Basel). 7 (2), 219-237 (2015).</li>
<li>Benincasa, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fungicidal+activity+of+five+cathelicidin+peptides+against+clinically+isolated+yeasts%5BTitle%5D)+AND+%22J+Antimicrob+Chemother%22%5BJournal%5D)">Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts.</a> J Antimicrob Chemother. 58 (5), 950-959 (2006).</li>
<li>CLSI. <a target="_blank" href="https://clsi.org/standards/products/microbiology/documents/m27s/">Reference Method for Broth Dilution Antifungal Susceptibiliy Testing of Yeasts; Approved Standard -Third Edition. CLSI document M27-A3</a>. , Clinical and Laboratory Standards Institute. Wayne, PA. (2008).</li>
<li>Guilhelmelli, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Activity+of+Scorpion+Venom-Derived+Antifungal+Peptides+against+Planktonic+Cells+of+Candida+spp.+and+Cryptococcus+neoformans+and+Candida+albicans+Biofilms%5BTitle%5D)+AND+%22Front+Microbiol%22%5BJournal%5D)">Activity of Scorpion Venom-Derived Antifungal Peptides against Planktonic Cells of Candida spp. and Cryptococcus neoformans and Candida albicans Biofilms.</a> Front Microbiol. 7, 1844(2016).</li>
<li>The European Committee on Antimicrobial Susceptibility Testing. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, version, 7.3.1 2017. , Available from:
 <a target="_blank" href="http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7_3_1_Yeast_testing__definitive.pdf">http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7_3_1_Yeast_testing__definitive.pdf</a> (2017).</li>
<li>Roongruangsree, U. T., Kjerulf-Jensen, C., Olson, L. W., Lange, L. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1111/j.1439-0434.1988.tb04474.x/full">Viability Tests for Thick Walled Fungal Spores (ex: Oospores of Peronospora manshurica).</a> Journal of Phytopathology. 123 (3), 244-252 (1988).</li>
<li>Boedijn, K. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trypan+blue+as+stain+for+fungi%5BTitle%5D)+AND+%22Stain+Technol%22%5BJournal%5D)">Trypan blue as stain for fungi.</a> Stain Technol. 31 (3), 115-116 (1956).</li>
<li>Goihman-Yahr, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Studies+on+plating+efficiency+and+estimation+of+viability+of+suspensions+of+Paracoccidioides+brasiliensis+yeast+cells%5BTitle%5D)+AND+%22Mycopathologia%22%5BJournal%5D)">Studies on plating efficiency and estimation of viability of suspensions of Paracoccidioides brasiliensis yeast cells.</a> Mycopathologia. 71 (2), 73-83 (1980).</li>
<li>Tati, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Histatin+5-spermidine+conjugates+have+enhanced+fungicidal+activity+and+efficacy+as+a+topical+therapeutic+for+oral+candidiasis%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis.</a> Antimicrob Agents Chemother. 58 (2), 756-766 (2014).</li>
<li>Petrou, M. A., Shanson, D. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Susceptibility+of+Cryptococcus+neoformans+by+the+NCCLS+microdilution+and+Etest+methods+using+five+defined+media%5BTitle%5D)+AND+%22J+Antimicrob+Chemother%22%5BJournal%5D)">Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media.</a> J Antimicrob Chemother. 46 (5), 815-818 (2000).</li>
<li>Zaragoza, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Process+analysis+of+variables+for+standardization+of+antifungal+susceptibility+testing+of+nonfermentative+yeasts%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts.</a> Antimicrob Agents Chemother. 55 (4), 1563-1570 (2011).</li>
<li>Rodriguez-Tudela, J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Influence+of+shaking+on+antifungal+susceptibility+testing+of+Cryptococcus+neoformans%3A+a+comparison+of+the+NCCLS+standard+M27A+medium%2C+buffered+yeast+nitrogen+base%2C+and+RPMI-2%25+glucose%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.</a> Antimicrob Agents Chemother. 44 (2), 400-404 (2000).</li>
<li>Beggs, W. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Growth+phase+in+relation+to+ketoconazole+and+miconazole+susceptibilities+of+Candida+albicans%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans.</a> Antimicrob Agents Chemother. 25 (3), 316-318 (1984).</li>
<li>Alcouloumre, M. S., Ghannoum, M. A., Ibrahim, A. S., Selsted, M. E., Edwards, J. E. Jr <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fungicidal+properties+of+defensin+NP-1+and+activity+against+Cryptococcus+neoformans+in+vitro%5BTitle%5D)+AND+%22Antimicrob+Agents+Chemother%22%5BJournal%5D)">Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.</a> Antimicrob Agents Chemother. 37 (12), 2628-2632 (1993).</li>
</ol>

The authors have nothing to disclose.

Microdilution tests can analyze the potential antifungal activity of a target compound using small quantities of the compound, and at the same time test it in a range of concentrations. Accordingly, this protocol is recommended as a first step in screening for potential new antifungal compounds. The protocol presented here is based on the M27-A3 protocol, initially designed to aid in the selection of antifungal therapy in clinics, and can be adapted to a variety of new antifungal compounds. Overall, this protocol can focus on the physicochemical features of the extract or compound. For example, a potential candidate in the assay may falsely appear ineffective because a compound in the media may block its interaction with the fungal cell, such as the effect of RPMI on Histatin 514. In this case, an alternate medium for when the RPMI interferes, is Yeast Nitrogen Base (YNB) buffer with MOPS pH 715.
The protocol also allows modifications in pre-growth conditions, inoculum concentration, incubation temperature, and for light-sensitive components, as long as the reference antifungal results are within the guidelines range. The reference antifungal should be based on the current therapy for the tested fungal species. Additionally, if there is a reference compound that is similar in nature to the potential drug &#8211; e.g., a known antimicrobial peptide with antifungal activity against the tested fungal model &#8211; it should be used as an additional reference control.
Pre-growth conditions can be altered to suit the fungi and research needs. As in the protocol, C. neoformans and C. albicans were grown at 30 &#176;C for better propagation. Nevertheless, this temperature can be changed depending on the fungi metabolism: for example, Paracoccidioides brasiliensis requires growth at 37 &#176;C to maintain its yeast form, and due to its slow duplication rate, needs to be grown for 5-7 days. Therefore, it is essential to understand the fungus characteristics for testing a potential new drug. Furthermore, the age and stage of growth of the cells used should be defined according to the purpose of each study and, most importantly, the initial incubation time should be established beforehand and maintained throughout all the tests to ensure reproducibility.
Equally, if the compound/extract, the reference antifungal, or diluent is sensitive to light, steps should be added to prevent its degradation, such as working with reduced light, covering the plates with foil, or placing the plates in a dark chamber during incubation times.
Moreover, the edge effect and evaporation can be diminished with the addition of water in empty wells, by not using the outer wells and filling them with water, or by placing the plate in a humid chamber.
One of the main limitations when using this method is its focus on the inhibitory activity of a tested compound, as opposed to distinguishing between fungicidal or fungistatic effects. Nevertheless, as the objective is a fast screening of the potential new antifungal, the initial visual assessment MIC with a clear positive (&#39;clear/non-turbidity&#39; wells) and a negative (&#39;turbidity&#39; wells) result, helps identify compounds of interest to study further, and therefore reducing the overall cost of screening for new compounds.
Since the mechanism of action of these new compounds is unknown, this same protocol can be used to determine the compound&#39;s ability to inhibit or kill fungal cells by adding a few extra steps, such as plating the positive wells or using live/dead dyes. Other minor modifications can be added to use the protocol for a checkerboard titration assay to identify any synergistic effects of the compound with other drugs.
Although the assay&#39;s reading is typically performed by visual analysis of fungal growth under different conditions compared to the growth in the well with no antifungal agent (negative/growth control), it can also be done by measuring its OD at 600 nm. However, although the OD measurement is accurate for homogenous solutions, some fungi grow in clumps thus breaking the precision of the method &#8211; e.g., Candida spp. as result of filamentation during the incubation period.
On the other hand, one of the major advantages of the protocol described here, in comparison to the CLSI M27-A3 guidelines, is that it takes into account aeration of the media for non-fermenting fungi, like C. neoformans. Also, the CLSI guidelines only uses a small initial inoculum, thus requiring extended periods of incubation for fungal growth and MIC definition. Some studies have demonstrated that higher initials inoculums and shaking the plate during incubation improve the antifungal susceptibility tests without significant effects on MIC determination16,17. Our protocol can precisely determine the MIC for new compounds against C. neoformans in a shortened incubation period, within 48 h, compared to 72 h suggested by CLSI guidelines.
Another advantage is that our protocol uses a 100 &#181;L final volume instead of 200 &#181;L recommended by CLSI guidelines, thus reducing the amount of the tested new compound required for the antifungal assay. However, evaporation of external wells may be a concern, but solutions already described in this section to reduce evaporation can be used without compromising the assay results.
Additionally, by performing the dilutions directly in the plate, and thus bypassing the CLSI dilution guidelines to use microcentrifuge tubes, multichannel pipettes can be used. This protocol assembly is less complicated than the one in the CLSI guidelines, and also uses fewer materials.
A critical step related to fungal cell preparation is the use of cells that are as fresh as possible. It is also crucial to perform all the assays with the cells at the same growth phase, since there are several reports in the literature about the differences in antifungal susceptibility when the culture ages18,19. A careful selection of reference strains is also essential. A very sensitive or rarely isolated species may not produce a clear picture of the antifungal potential. By the same token, it is helpful to avoid sub-culturing steps as to not add many variables to the assay. For example, for Candida strains (which grow faster), we prefer to bypass the agar plate step by making the inoculum directly into the liquid media.
Remember that the physicochemical features of the extract or compound to be tested are important to consider. For example, if the extract or compound needs to be dissolved in solvents other than water, must make sure to have an appropriate fungal growth control that includes the same solvent concentration with the fungus alone. This is to guarantee that any growth inhibition observed is not due to the solvent instead of the tested compound or extract. In this case, it might be better to follow the CLSI-M27A3 recommendations for DMSO diluted antifungal drugs, such as dissolving the drug in a concentration at least 100 times higher than the highest tested concentration to reduce the percentage of the solvent in the plate.
Regarding stability, it is recommended to keep small aliquots of the analyzed extracts or compounds. By storing the volume necessary for a single assay at the appropriate temperature, excessive manipulation of the aliquot and, if the extracts or compounds are stored frozen, freeze-thaw cycles can be avoided.
Finally, one of the most fundamental steps is the accuracy of the microplate serial dilution, given that any pipetting error will be propagated along the consecutive dilutions. Henceforth, pipette precision and proper pipetting techniques are paramount to ensure reproducibility. So, it is imperative to use calibrated pipettes and always check if the volume added and removed from each well is correct. Make sure that residue or vestige from the drug does not remain in the pipette tip. If the compound tends to stick to the tip, it might be better to switch tips between the dilutions.

Fungal infections have become an important medical concern in recent decades, having considerably increased mainly due to a rise in the number of immunocompromised individuals such as those undergoing cancer treatment and those living with HIV/AIDS or transplanted organs1,2. However, a very limited array of available antifungal drugs and the increasing number of reports on fungal resistance to them contribute to the major problems regarding the therapeutics of systemic mycoses3.
A potential source of new antifungal compounds are antimicrobial peptides (AMPs), small cationic peptides produced by many organisms as part of their innate immune response to infection4. Nevertheless, the screening method to test these compounds against fungal pathogens is not standardized. Different procedures have been used to assess the antifungal activity of AMPs, sometimes for the same model microorganism5,6,7. These differences and the lack of detail in some protocols complicate comparisons between compounds and hampers reproducibility.
One way to standardize the testing of new drug candidates is to follow guidelines used to define antifungal susceptibility in clinical settings, such as the Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines. However, these antifungal sensitivity tests are too restrictive, and do not take into consideration variation in metabolism across species, as they were only established for a few select agents. For example, they do not take into account the metabolic needs of non-fermenting yeasts.
This protocol allows the assessment of activity of prospective antifungal compounds, and is implemented here for the search for antifungal peptides. It is based on the broth microdilution susceptibility test from the CLSI M27-A3 guidelines with modifications that optimize the screening of new compounds8,9. These changes allow for the use of small amounts of compound, variations in temperature or initial inoculum, and different media for optimal pre-test growth, while standardizing the results with the use of reference antifungals as controls. This method, with the use of multi-well culture plates, makes it possible to quickly and reliably screen a large number of compounds.
Due to its inherent flexibility, this protocol can be used with different chemical classes of compounds and against other microorganisms, with few adaptations.

<table><tbody><tr><td>&lt;strong&gt;Media and Reagents&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>RPMI 1640 medium with l-glutamine, without sodium bicarbonate</td><td>Thermo Fisher</td><td>31800-022</td><td></td></tr><tr><td>3-(&lt;em&gt;N&lt;/em&gt;-morpholino) propane sulfonic acid&lt;em&gt; (MOPS) (o que a gente usa tem um s&amp;oacute;dio, completa o nome dele please)&lt;/em&gt;</td><td>Sigma-Aldrich</td><td></td><td>Use to buffer 2X RPMI medium</td></tr><tr><td>Sodium chloride (NaCl)</td><td>Din&amp;acirc;mica</td><td>1528-1</td><td>137 mM for Phosphate buffered saline (PBS)</td></tr><tr><td>Potassium chloride (KCl)</td><td>J.T.Baker</td><td>3040-01</td><td>2.7 mM for Phosphate buffered saline (PBS)</td></tr><tr><td>Sodium phosphate dibasic (Na2HPO4)</td><td>Sigma-Aldrich</td><td>V000129</td><td>10 mM for Phosphate buffered saline (PBS)</td></tr><tr><td>Potassium dihydrogen phosphate (KH2PO4)</td><td>Sigma-Aldrich</td><td>60230</td><td>2 mM for Phosphate buffered saline (PBS)</td></tr><tr><td>BD Difco Sabouraud dextrose broth</td><td>BD</td><td>238230</td><td></td></tr><tr><td>BD Difco Sabouraud Dextrose Agar</td><td>BD</td><td>210950</td><td></td></tr><tr><td>Glycerol</td><td>Sigma-Aldrich</td><td>V000123</td><td>35% for (solu&amp;ccedil;&amp;atilde;o de estoque? Criopreserva&amp;ccedil;&amp;atilde;o?)</td></tr><tr><td>Sterile water</td><td></td><td></td><td>Para dilui&amp;ccedil;&amp;atilde;o das drogas na dilui&amp;ccedil;&amp;atilde;o seriada</td></tr><tr><td>&lt;strong&gt;Antifungal drugs&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Amphotericin B</td><td>Sigma-Aldrich</td><td>A2942</td><td></td></tr><tr><td>Fluconazole</td><td>Sigma-Aldrich</td><td>F8929</td><td></td></tr><tr><td>Caspofungin</td><td>Sigma-Aldrich</td><td>PHR1160</td><td></td></tr><tr><td>&lt;strong&gt;Plastics&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>50 mL conical tube</td><td>Sarstedt</td><td>62.547.254</td><td></td></tr><tr><td>Dish petri</td><td>J.Prolab</td><td>0304-5</td><td></td></tr><tr><td>96 well plate</td><td>Corning</td><td>3595</td><td></td></tr><tr><td>Sterile Solution Reservoir</td><td>KASVI</td><td>K30-208</td><td>Use to pippet the solutions using the multichannel pippet</td></tr><tr><td>&lt;strong&gt;Equipment and other materials&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Optical microscope</td><td>Nikon</td><td>E200MV</td><td></td></tr><tr><td>Centrifugue</td><td>Thermo Fisher</td><td>MegaFuge 16R</td><td></td></tr><tr><td>Incubator</td><td>Ethik Technology</td><td>403-3D</td><td>Set to 37&amp;deg; C</td></tr><tr><td>Shaker</td><td>New Brunswick Scientific</td><td>Excella E25</td><td>Set to 37&amp;deg; C, 200 RPM</td></tr><tr><td>Cell counting chamber, Neubauer</td><td>BOECO Germany</td><td>BOE 13</td><td></td></tr><tr><td>Multichannel pipette</td><td>HTL</td><td>5123</td><td></td></tr></tbody></table>

broth microdilution in vitro screening: an easy and fast method to detect new antifungal compounds

Fungal infections have become an important medical condition in the last decades, but the number of available antifungal drugs is limited. In this scenario, the search for new antifungal drugs is necessary. The protocol reported here details a method to screen peptides for their antifungal properties. It is based on the broth microdilution susceptibility test from the Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines with modifications to suit the research of antimicrobial peptides as potential new antifungals. This protocol describes a functional assay to evaluate the activity of antifungal compounds and may be easily modified to suit any particular class of molecules under investigation. Since the assays are performed in 96-well plates using small volumes, a large-scale screening can be completed in a short amount of time, especially if carried out in an automation setting. This procedure illustrates how a standardized and adjustable clinical protocol can help the bench-work pursuit of new molecules to improve the therapy of fungal diseases.

The MIC is defined as the lowest antimicrobial compound concentration that completely inhibits visible fungal growth at the end of the incubation period. Since the objective of this protocol is to have a fast method to screen potential antifungals, any well with clear media similar to the blank wells is considered a positive result, whereas any well with turbidity analogous to the negative/growth control wells is considered negative. However, if there is an interest in knowing whether a given AMP is fungistatic or fungicidal, the media from the positive wells can also be plated onto Sabouraud Dextrose Agar or checked by another viability test.
Given that the mechanism of action of a novel compound is unknown, it is therefore essential to verify if the reference antifungal falls within the expected range for the fungal isolate (check official guidelines, tables, or data in literature) before checking the tested MIC for the compound (in this case, an AMP; Figure 1 and Figure 2) to confirm that conditions are ideal. If it does not fall in the respected range, it will be necessary to rerun the experiment since it will be impossible to determine if any changes observed are due solely to the tested compound. It is equally crucial to observe all wells under an optical microscope before and after the incubation period to check for changes in morphology and contamination.
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/57127/57127fig1.jpg" /> 
Figure 1. Evaluation of antifungal activity for three peptides against Cryptococcus neoformansusing the broth microdilution assay. Fungus concentration is at 1 x 104 cells/mL. Three peptides were tested (AMP1, columns 1 to 3; AMP2, columns 5 to 7; AMP3, columns 8 to 10) with concentrations ranging from 100 &#181;M (row A) to 0.78 &#181;M (row H). Growth control and blank are in columns 11 and 12, respectively. The image was acquired with a digital camera after 48 h of incubation. <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57127/57127fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/57127/57127fig2.jpg" /> 
Figure 2. Evaluation of antifungal activity for three peptides against Candida albicans using the broth microdilution assay. Fungus concentration is at 2 x 103 cells/mL. Three peptides were tested (AMP1, columns 1 to 3; AMP2, columns 4 to 6; AMP3, columns 7 to 9) with concentrations ranging from 100 &#181;M (row A) to 0.78 &#181;M (row H). Growth control and blank were included in the assay, but do not appear in the photo. The image was acquired with a digital camera after 48 h of incubation. <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57127/57127fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
As observed in Figure 1 and Figure 2, 48 h is enough time to distinguish positive and negative wells visually for both C. neoformans and C. albicans. It is noteworthy that the results for C. neoformans were obtained 24 h earlier than under the CSLI guidelines without the modifications. For each triplicate, the positive and negative well, and therefore the MIC for each compound, are easily discernible. This allows for fast MIC determination for multiple compounds as well as for choosing which molecules merit further investigation. Meanwhile, Figure 3 is an example a poor result, likely from improper pipetting during the dilution step. This can be observed in column 5, row C, where a difference in C. neoformans growth is present across replicates (columns 5-7).
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/57127/57127fig3.jpg" /> 
Figure 3. Example of an error in technical replicates in a serial dilution assay. The image shows a serial dilution of AMPs ranging from 100 &#181;M (row A) to 0.78 &#181;M (row H). Differences in C. neoformans growth are present between replicates in columns 5-7, row C, most likely due to pipetting error during dilution preparation. <a href="https://cloudflare-jove-com.remotexs.ntu.edu.sg/files/ftp_upload/57127/57127fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
As for the interpretation of the plates, in Figure 1 there is an antifungal assay for three different AMPs against C. neoformans, located at columns 1-3 for AMP1, columns 5-7 for AMP2, and columns 8-10 for AMP3 with concentrations varying from 100 &#181;M (row A) to 0.78 &#181;M (row H). The negative/growth control was placed in column 11, rows A to C, while the blank control was placed in column 12, rows A to C. For AMP1 (columns 1-3, rows A-C) and AMP2 (columns 5-7, rows A-D), note that at a higher concentration the media is translucent and there is no visible growth. In contrast, at lower concentrations the wells are opaque (columns 1-3, rows D-H and columns 5-7, rows E-H). Therefore, row C is considered to contain the MIC for AMP1, while the MIC for AMP2 is in row D, that is to say, 25 &#181;M and 12.5 &#181;M, respectively. AMP3 will have to be re-evaluated, as the fungus grew in all concentrations tested. The reexamination for AMP3 is necessary to determine the cause, which could be that the test medium is interfering with the antifungal activity of the compound, microbial contamination, or a higher resistance of the fungus to the agent tested. For the last possibility, it will be necessary to increase the concentration range tested. As observed, the no-inhibition and control wells are homogeneous, so they could also be assessed by OD measurement at 600 nm.
As for Figure 2, three distinct peptides were tested against C. albicans. The MICs for AMP1 (columns 1-3), AMP2 (columns 4-6), and AMP3 (columns 7-9) were 50 &#181;M, 6 &#181;M, and 25 &#181;M, respectively. C. albicans, due to filamentation in the incubation temperature, can be observed in clumps in the no-inhibition and control wells, making it difficult to use OD measurement for reading.
Sometimes, no growth is observed in the wells. This may be due to a toxin contamination in the media (in which case the growth controls also show no growth) or a higher susceptibility to the agent (in which case, the growth controls show growth). Accordingly, for the latter case, a decrease in the concentration range might be necessary.
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Medium</td>
			<td colspan="2">Preparation</td>
		</tr>
		<tr>
			<td rowspan="4">2X Roswell Park Memorial Institute (RPMI) 1640 medium &#8211; 500 mL</td>
			<td colspan="2">10.4 g RPMI-1640 (supplemented with L-glutamine and phenol red; without bicarbonate)</td>
		</tr>
		<tr>
			<td colspan="2">330 mM 3-(N-morpholino) propane sulfonic acid (MOPS)</td>
		</tr>
		<tr>
			<td colspan="2">Adjust to pH 7.0 with NaOH</td>
		</tr>
		<tr>
			<td colspan="2">Sterilize by filtration (0.22 &#181;M filter)</td>
		</tr>
		<tr>
			<td rowspan="5">Phosphate buffered saline (PBS)</td>
			<td colspan="2">137 mM NaCl</td>
		</tr>
		<tr>
			<td colspan="2">2.7 mM KCl</td>
		</tr>
		<tr>
			<td colspan="2">10 mM Na2HPO4</td>
		</tr>
		<tr>
			<td colspan="2">2 mM KH2PO4</td>
		</tr>
		<tr>
			<td colspan="2">Autoclave at 121&#176;C for 15 minutes.</td>
		</tr>
		<tr>
			<td rowspan="3">Sabouraud dextrose broth </td>
			<td colspan="2">15 g of the powder in 500 mL of distilled water.</td>
		</tr>
		<tr>
			<td colspan="2">Adjust to pH 7.0 with NaOH</td>
		</tr>
		<tr>
			<td colspan="2">Autoclave at 121&#176;C for 15 minutes.</td>
		</tr>
		<tr>
			<td rowspan="3">Sabouraud Dextrose Agar </td>
			<td colspan="2">32.5 g of the powder in 500 mL of distilled water.</td>
		</tr>
		<tr>
			<td colspan="2">Adjust to pH 7.0 with NaOH</td>
		</tr>
		<tr>
			<td colspan="2">Autoclave at 121&#176;C for 15 minutes.</td>
		</tr>
	</tbody>
</table>
Table 1. Media and reagent preparation.

Watch this Scientific Journal Video about Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds at JoVE.com

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

An easy and adaptable broth microdilution method for screening antifungal compounds and extracts.

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Fungal infections have become an important medical condition in the last decades, but the number of available antifungal drugs is limited. In this ...

broth-microdilution-vitro-screening-an-easy-fast-method-to-detect-new

Nanyang Technological University

Research

JoVE Journal

Biology

18.8K Views.  University of Brasília. An easy and adaptable broth microdilution method for screening antifungal compounds and extracts.

Video: Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms

Candida albicans remains the most frequent cause of fungal infections in an expanding population of compromised patients and candidiasis is now the third most common infection in US hospitals. Different manifestations of candidiasis are associated with biofilm formation, both on host tissues and/or medical devices (i.e. catheters). Biofilm formation carries negative clinical implications, as cells within the biofilms are protected from host immune responses and from the action of antifungals. We have developed a simple, fast and robust in vitro model for the formation of C. albicans biofilms using 96 well microtiter-plates, which can also be used for biofilm antifungal susceptibility testing. The readout of this assay is colorimetric, based on the reduction of XTT (a tetrazolium salt) by metabolically active fungal biofilm cells. A typical experiment takes approximately 24 h for biofilm formation, with an additional 24 h for antifungal susceptibility testing. Because of its simplicity and the use of commonly available laboratory materials and equipment, this technique democratizes biofilm research and represents an important step towards the standardization of antifungal susceptibility testing of fungal biofilms.

A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms

We describe a simple, rapid and robust method for the formation of Candida albicans biofilms using 96 well microtiter plates and its utility in antifungal susceptibility testing of cells within biofilms.

Candida albicans remains the most frequent cause of fungal infections in an expanding population of compromised patients and candidiasis is now the third ...

Immunology and Infection

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Candida albicans remains the main etiological agent of candidiasis, which currently represents the fourth most common nosocomial bloodstream infection in US hospitals1. These opportunistic infections pose a growing threat for an increasing number of compromised individuals, and carry unacceptably high mortality rates. This is in part due to the limited arsenal of antifungal drugs, but also to the emergence of resistance against the most commonly used antifungal agents. Further complicating treatment is the fact that a majority of manifestations of candidiasis are associated with the formation of biofilms, and cells within these biofilms show increased levels of resistance to most clinically-used antifungal agents2. Here we describe the development of a high-density microarray that consists of C. albicans nano-biofilms, which we have named CaBChip3. Briefly, a robotic microarrayer is used to print yeast cells of C. albicans onto a solid substrate. During printing, the yeast cells are enclosed in a three dimensional matrix using a volume as low as 50 nL and immobilized on a glass substrate with a suitable coating. After initial printing, the slides are incubated at 37 &deg;C for 24 hours to allow for biofilm development. During this period the spots grow into fully developed "nano-biofilms" that display typical structural and phenotypic characteristics associated with mature C. albicans biofilms (i.e. morphological complexity, three dimensional architecture and drug resistance)4. Overall, the CaBChip is composed of ~750 equivalent and spatially distinct biofilms; with the additional advantage that multiple chips can be printed and processed simultaneously. Cell viability is estimated by measuring the fluorescent intensity of FUN1 metabolic stain using a microarray scanner. This fungal chip is ideally suited for use in true high-throughput screening for antifungal drug discovery. Compared to current standards (i.e. the 96-well microtiter plate model of biofilm formation5), the main advantages of the fungal biofilm chip are automation, miniaturization, savings in amount and cost of reagents and analyses time, as well as the elimination of labor intensive steps. We believe that such chip will significantly speed up the antifungal drug discovery process.

Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening

We have developed a high-density microarray platform consisting of 3D nano-biofilms of C. albicans called CaBChip. The susceptibility profile of drugs tested on a CaBChip is comparable to the conventional 96-well plate model, suggesting that the fungal chip is ideally suited for true high-throughput screening of antifungal drugs.

Candida  albicans remains the main etiological agent of candidiasis, which  currently represents the fourth most common nosocomial bloodstream infection ...

Bioengineering

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

The protocol described is based on a plug-transfer technique that allows accurate determination of microorganism quantities and their developmental stages. A specified number of spores are spread on an agar plate. This agar plate is incubated for a defined period to allow the fungi to reach the expected developmental stage, except for spores where incubation is not required. Agar plugs covered by spores, hyphae, or mycelium are next withdrawn and transferred onto agar media containing the antifungal compound to be tested either placed at a distance from the fungi or in contact. This method is applicable to test both liquid extracts and solid samples (powders). It is particularly well suited for quantifying the relative contributions of volatile and non-volatile agents in bioactive mixtures and for determining their effects, specifically on spores, early hyphae, and mycelium.
The method is highly relevant for the characterization of the antifungal activity of biocontrol products, notably plant-derived products. Indeed, for plant treatment, the results can be used to guide the choice of mode of application and to establish the trigger thresholds.

We describe a modified agar-based method designed to quantify the antifungal effects of plant-derived products. Both volatile and non-volatile contributions to the antifungal activity can be assessed through this protocol. In addition, efficacy against fungi can be measured at key developmental stages in a single experimental setup.

The protocol described is based on a plug-transfer technique that allows accurate determination of microorganism quantities and their developmental ...

Environment

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Despite the availability of therapy and vaccine, tuberculosis (TB) remains one of the most deadly and widespread bacterial infections in the world. Since several decades, the sudden burst of multi- and extensively-drug resistant strains is a serious threat for the control of tuberculosis. Therefore, it is essential to identify new targets and pathways critical for the causative agent of the tuberculosis, Mycobacterium tuberculosis (Mtb) and to search for novel chemicals that could become TB drugs. One approach is to set&#160;up methods suitable for the genetic and chemical screens of large scale libraries enabling the search of a needle in a haystack. To this end, we developed a phenotypic assay relying on the detection of fluorescently labeled Mtb within fluorescently labeled host&#160;cells using automated confocal microscopy. This in vitro assay allows an image based quantification of the colonization process of Mtb&#160;into the host and was optimized for the 384-well microplate format, which is proper for screens of siRNA-, chemical compound- or Mtb mutant-libraries. The images are then processed for multiparametric analysis, which provides read&#160;out inferring on the pathogenesis of Mtb&#160;within host cells.

Here, we describe a phenotypic assay applicable to the High-throughput/High-content screens of small-interfering synthetic RNA (siRNA), chemical compound, and Mycobacterium tuberculosis mutant libraries. This method relies on the detection of fluorescently labeled Mycobacterium tuberculosis within fluorescently labeled host&#160;cell using automated confocal microscopy.

Despite the availability of therapy and vaccine, tuberculosis (TB) remains one of the most deadly and widespread bacterial infections in the world. Since ...

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Antimicrobial susceptibility testing (AST) is performed to assess the in vitro activity of antimicrobial agents against various bacteria. The AST results, which are expressed as minimum inhibitory concentrations (MICs) are used in research for antimicrobial development and monitoring of resistance development and in the clinical setting for antimicrobial therapy guidance. Dalbavancin is a semi-synthetic lipoglycopeptide antimicrobial agent that was approved in May 2014 by the Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive organisms. The advantage of dalbavancin over current anti-staphylococcal therapies is its long half-life, which allows for once-weekly dosing. Dalbavancin has activity against Staphylococcus aureus (including both methicillin-susceptible S. aureus [MSSA] and methicillin-resistant S. aureus [MRSA]), coagulase-negative staphylococci, Streptococcus pneumoniae, Streptococcus anginosus group, &#946;-hemolytic streptococci and vancomycin susceptible enterococci. Similar to other recent lipoglycopeptide agents, optimization of CLSI and ISO broth susceptibility test methods includes the use of dimethyl sulfoxide (DMSO) as a solvent when preparing stock solutions and polysorbate 80 (P80) to alleviate adherence of the agent to plastic. Prior to the clinical studies and during the initial development of dalbavancin, susceptibility studies were not performed with the use of P-80 and MIC results tended to be 2-4 fold higher and similarly higher MIC results were obtained with the agar dilution susceptibility method. Dalbavancin was first included in CLSI broth microdilution methodology tables in 2005 and amended in 2006 to clarify use of DMSO and P-80. The broth microdilution (BMD) procedure shown here is specific to dalbavancin and is in accordance with the CLSI and ISO methods, with step-by-step detail and focus on the critical steps added for clarity.

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Here, we present a protocol for determination of dalbavancin susceptibility of clinically relevant Gram-positive bacteria using a broth microdilution reference methodology.

Antimicrobial susceptibility testing (AST) is performed to assess the in vitro activity of antimicrobial agents against various bacteria. The AST results, ...

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of morbidity and mortality worldwide. With the increased spread of multi drug-resistant TB (MDR-TB), there is a real urgency to develop new therapeutic strategies against M. tuberculosis infections. Traditionally, compounds are evaluated based on their antibacterial activity under in vitro growth conditions in broth; however, results are often misleading for intracellular pathogens like M. tuberculosis since in-broth phenotypic screening conditions are significantly different from the actual disease conditions within the human body. Screening for inhibitors that work inside macrophages has been traditionally difficult due to the complexity, variability in infection, and slow replication rate of M. tuberculosis. In this study, we report a new approach to rapidly assess the effectiveness of compounds on the viability of M. tuberculosis in a macrophage infection model. Using a combination of a cytotoxicity assay and an in-broth M. tuberculosis viability assay, we were able to create a screening system that generates a comprehensive analysis of compounds of interest. This system is capable of producing quantitative data at a low cost that is within reach of most labs and yet is highly scalable to fit large industrial settings.

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

We have developed a modular high-throughput screening system for discovering novel compounds against Mycobacterium tuberculosis, targeting intracellular and in-broth growing bacteria as well as cytotoxicity against the mammalian host cell.

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of morbidity and mortality worldwide. With the increased spread ...

Competitive Genomic Screens of Barcoded Yeast Libraries

By virtue of advances in next generation sequencing technologies, we have access to new genome sequences almost daily. The tempo of these advances is accelerating, promising greater depth and breadth. In light of these extraordinary advances, the need for fast, parallel methods to define gene function becomes ever more important. Collections of genome-wide deletion mutants in yeasts and E. coli have served as workhorses for functional characterization of gene function, but this approach is not scalable, current gene-deletion approaches require each of the thousands of genes that comprise a genome to be deleted and verified. Only after this work is complete can we pursue high-throughput phenotyping. Over the past decade, our laboratory has refined a portfolio of competitive, miniaturized, high-throughput genome-wide assays that can be performed in parallel. This parallelization is possible because of the inclusion of DNA 'tags', or 'barcodes,' into each mutant, with the barcode serving as a proxy for the mutation and one can measure the barcode abundance to assess mutant fitness. In this study, we seek to fill the gap between DNA sequence and barcoded mutant collections. To accomplish this we introduce a combined transposon disruption-barcoding approach that opens up parallel barcode assays to newly sequenced, but poorly characterized microbes. To illustrate this approach we present a new Candida albicans barcoded disruption collection and describe how both microarray-based and next generation sequencing-based platforms can be used to collect 10,000 - 1,000,000 gene-gene and drug-gene interactions in a single experiment.

We have developed comprehensive, unbiased genome-wide screens to understand gene-drug and gene-environment interactions. Methods for screening these mutant collections are presented.

By virtue of advances in next generation sequencing technologies, we have access to new genome sequences almost daily.  The tempo of these advances is ...

High-Throughput Screening Assay for Mycobacterium abscessus Using Dual Reporters

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Mycobacterium abscessus (Mab) infections are challenging to treat due to high intrinsic drug resistance, comparable to multidrug-resistant tuberculosis. Treatments are extremely ineffective and based on a multi-drug regimen, resulting in low patient compliance. Consequently, the scientific community is urged to identify new and effective drugs to treat these infections. One of the strategies employed to this end is drug repurposing - the process of identifying new therapeutic opportunities for existing drugs in the market, circumventing the time required to establish pharmacokinetic and safety profiles of new drugs. With most studies on drug development against Mab relying on traditional and time-consuming methods, an assay for high-throughput drug screening was developed against mycobacteria using an in house developed double-reporter strain of Mab. Using liquid-handling robotics, automated microscopy, and analysis, alongside in house developed double reporter strains, bacterial viability can be rapidly measured using two different readouts, luminescence and fluorescence, without adding reagents or performing any extra steps. This reduces time and variability between assays, a major advantage for high-throughput screenings. The described protocol was validated by screening a library of 1280 compounds. The obtained results were corroborated by the literature, with efficient detection of active compounds. Thus, this work fulfilled the aim of supplying the field with a new tool to help fight this extremely drug-resistant bacteria.

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

This study developed an assay for high-throughput screening against Mycobacterium abscessus with a&#160;recently created double reporter strain, using fluorescence and luminescence to assess bacterial viability quickly. This protocol will be relevant for researchers aiming to screen new drugs against this drug-resistant bacteria.

Mycobacterium abscessus (Mab) infections are challenging to treat due to high intrinsic drug resistance, comparable to multidrug-resistant tuberculosis. ...

An In Vitro Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilm

Source: Chandley, P., et al. <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/64425">A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms.</a> J. Vis. Exp. (2022).
This video demonstrates an in vitro technique to study the effect of antibodies on fungal biofilms. The pathogenic fungus Candida tropicalis secretes a virulence factor secreted aspartyl proteinase 2 (Sap2), facilitating biofilm formation. Upon introducing a heat-inactivated serum containing Sap2-specific antibodies that inhibit biofilm maturation, the viability of the fungal cells is assessed using a chromogenic assay.

Test in vitro w celu oceny wpływu przeciwciał na biofilm Candida tropicalis

1. C. tropicalis&#160;biofilm formation

	Prepare&#160;Candida&#160;biofilms in a 96-well flat-bottomed polystyrene microtiter plate as described earlier ...

JoVE Encyclopedia of Experiments

Immunology

Antibody-Based Technologies

Characterization and Functional Analysis

An In Vitro Broth Microdilution Assay for the Screening of Antifungal Compounds

Source: de-Souza-Silva, C. M., et al. <a href="https://app-jove-com.remotexs.ntu.edu.sg/v/57127">Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds.</a> J. Vis. Exp. (2018).
This video demonstrates an in vitro assay to screen antifungal compounds using a broth microdilution assay. Test compounds are serially diluted in a microtiter plate and incubated with a fungal inoculum. Post-incubation, the plate is examined for wells without visible fungal growth to assess the antifungal potential of the test compounds and their minimum inhibitory concentration (MIC).

Test mikrorozcieńczenia bulionu in vitro do badań przesiewowych związków przeciwgrzybiczych

1. Solutions and Media

	Prepare 2X Roswell Park Memorial Institute (RPMI) 1640 medium, phosphate-buffered saline (PBS), Sabouraud dextrose broth, and ...

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Podsumowanie

Przeglądaj więcej filmów

A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Competitive Genomic Screens of Barcoded Yeast Libraries

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Test in vitro w celu oceny wpływu przeciwciał na biofilm Candida tropicalis

Test mikrorozcieńczenia bulionu in vitro do badań przesiewowych związków przeciwgrzybiczych